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Background. Antiretroviral therapy (ART) administered in clinical trial settings virtually eliminates the sexual
transmission of human immunodeficiency virus (HIV) in serodiscordant couples, but effectiveness of treatment as
prevention in the community is debated. Conflicting results from previous analyses in a Chinese cohort underscore
the importance of determining effectiveness of ART delivered in resource limited settings.
Methods. All available years of data (2006–2012) from local disease control records of HIV patients and their
seronegative spouses in Henan Province, China, were analyzed using marginal structural Cox models to estimate the
effect of ART in the initially infected partner his or her partner’s HIV seroconversion risk.
Results. We observed 157 seroconversion events in 4916 serosdiscordant couples, for an incidence rate of 0.59
cases per 100 person-years (PY) (95% confidence interval [CI], .51–.70). Of these, 84 occurred after the index partner
had initiated ART (0.43/100PY; 95% CI, .35–.53) and 73, whereas index partners were untreated (5.87/100 PY; 95%
CI, 4.65–7.42). In a marginal structural Cox model weighted for confounding and censoring, the hazard ratio (HR)
for HIV transmission was 0.52 (95% CI, .34–.82). ART efficacy varied significantly by time period; least effective in
the early phase from 2006 to 2008 (HR, 0.68; 95% CI, .34–1.36) but far more protective from 2009 onward (HR, 0.33;
95% CI, .20–.55).
Conclusions. ART can provide HIV-infected persons in resource-limited setting substantial protection against
sexual transmission. Effectiveness in the Henan cohort appears to have increased over time, suggesting that quality of
care and service infrastructure may be integral to successful use of treatment for prevention.
Keywords. HIV treatment as prevention; HIV/AIDS; China; serodiscordant couples; sexual transmission.
Since 2012, several human immunodeficiency virus
(HIV) treatment guidelines have begun calling for
immediate treatment of all HIV-infected persons
regardless of CD4 cell count [1–3]. The guideline
changes are attributable, in part, to results of a
clinical trial showing that antiretroviral treatment
(ART) can stop sexual HIV transmission [4], as well
as evidence that earlier ART reduces HIV morbidity
and mortality [5].
Supporters of rapid rollout of “treatment as preven-
tion” strategies argue that the effect is already visible in
areas where broader ART access has coincided with de-
clines in measured sexual transmission of HIV [6, 7].
However exceptions to this pattern [8] and the potential
risks of rapid rollout such as widespread emergence of
drug resistance [9] or changes in risk behaviors [10],
have tempered enthusiasm. In resource-poor settings,
limited access to the resources required for durable
viral suppression—optimal drug regimens and routine
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laboratory monitoring, for example—have prompted calls for
research to inform treatment as prevention guidelines adapted
to these locations [11].
Of about a dozen observational studies reporting on the real
world effect of ART on sexual HIV transmission by following se-
rodiscordant couples, in which only 1 partner is infected [12, 13],
only 3 have followed those receiving routine care in resource-
limited settings (the remainder tracked patients in wealthy coun-
tries or who received specialized care as part of scientific research
studies). One of these 3 studies reported that ART prevented
linked HIV transmission in couples from the southern Chinese
province of Yunnan, though the uniqueness of the cohort—the
initially infected (or “index”) partners were overwhelming male
(78.7%), with about half reporting historic drug use (45.1%)—
and high loss of follow-up among untreated couples, limited gen-
eralizability of the results [13]. Notably, the remaining 2 reports
from Uganda [14] and Henan Province in China [15], both re-
ported a lack of protective immunity attributable to the index
partner’s ART use. Follow-up of the Henan cohort has been on-
going, and an analysis of a later phase of follow-up showed that
ARTwas instead highly protective against transmission [16], rais-
ing further questions about the relationship between ART expo-
sure and HIV transmission in nontrial settings.
The Chinese government provides free HIV testing and uni-
versal ART through the existing healthcare system, in many
cases managed by nonphysician clinicians [17], which provides
a realistic version of proposed test and treat strategies [18]. The
purpose of the current report is to investigate how well ART can
work under such conditions so as to inform future program-
ming for the use of treatment as prevention, particularly in re-
source poor settings.
METHODS
Study Setting and Data Sources
The Henan HIV serodiscordant couple cohort resulted from a
regional HIV epidemic largely attributed to unsanitary blood
and plasma selling practices prevalent in the mid-1990s [19].
Government crackdowns ended these practices by 1997, at
which time between 50 and 170 thousand persons in the prov-
ince were estimated to be living with HIV [20, 21]. Over one-
third of HIV-infected persons in Henan live in the prefecture
where the data used in this report were collected [15].
In 2006 the prefectural disease control center began enroll-
ment of an open cohort of HIV serodiscordant couples to
track HIV transmission in married couples. According to local
guidelines, eligible couples were (1) registered residents of the
study prefecture, (2) over 16 years of age (the age of legal con-
sent in China), (3) in a stable marriage (no separation nor
divorce), (4) in a HIV serodiscordant couple at the time of enroll-
ment, and (5) willing to provide informed consent. HIV status of
both partners was confirmed at enrollment through enzyme-
linked immunosorbent assay (ELISA; Lizhu, Zhuhai, Guangdong
Province; Xinzhuang, Xiamen, Fujian Province), and positive test
results were confirmed by Western blot assay (Ou’ya, Hangzhou,
Zhejiang Province), both of which were carried out at the county
or prefectural level disease control center laboratories.
Eligible couples participated in annual surveys consisting of pri-
vate and separate face-to-face interviews for each partner in their
native dialect with trained county-level disease control staff. Par-
ticipants provided information on demographics and behaviors
over the previous year including sexual contact inside and outside
the primary partnership, diagnosis of sexually transmitted infec-
tions, drug use, and history of migration for work. The initially
HIV-infected index partners provided additional medical history
including ART use, and initially uninfected (or “nonindex”) part-
ners were screened for antibodies to HIV, with those testing pos-
itive referred to their local county disease control center for
confirmatory testing and treatment eligibility screening.
Exposure, Outcome, and Other Covariates
The primary outcome for this analysis was time to HIV serocon-
version in the initially uninfected partner of couples participating
in at least 2 study visits between 2006 and 2012. Seroconversion
was calculated as the midpoint between the date of the last HIV-
negative or indeterminate test, and three months before the date of
the first HIV-positive test to provide an average window period for
seroconversion. Couples experiencing the outcome were censored
in the interval in which estimated seroconversion occurred; those
who remained discordant throughout the study were censored on
the date of their last HIV-negative test date. Seroconversion events
were manually validated by comparing test results and dates in the
national HIV surveillance database, a centralized web-based system
towhich local disease control authorities report all newly identified
HIV cases. If results differed between the 2 sets of records, infor-
mation from the national surveillance database was used.
The primary exposure was time-varying ART use by the index
partner. As with the outcome, we validated treatment status using
records in the national ART database, information from which
was given priority where discrepancies occurred. Additional
index partner covariates including disease stage, AIDS related
signs and symptoms, and CD4 cell count were linked from the
national epidemiology and treatment databases using a unique
identifier. Disease stage was determined using all other clinical in-
formation available when CD4 count was not recorded.
Statistical Analyses
To minimize potential bias induced by differences in transmis-
sion risk among patients initiating therapy at different times, we
restricted analysis to those unexposed to ART at baseline. This
new user design [22] eliminates the bias induced by under-
ascertainment of events likely to occur early in the course of
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therapy, as well as by our inability to control for baseline factors
that are themselves affected by the treatment (eg, disease stage).
Due to very low rates of treatment termination (0.06%), all new
users of ART were assumed to continue therapy until they were
censored through an event, loss to follow-up, couple breakup, or
death of either partner. Variables for which information was
missing for more than 20% of the sample were multiply imput-
ed using Markov Chain Monte Carlo simulation [23].
We used marginal structural Cox proportional hazard mod-
els [24] to estimate the association between index partner ART
use and time to HIV seroconversion in nonindex partners. To
mitigate bias from time-varying confounding variables that are
also potentially affected by prior treatment, we weighted our
model with the inverse probability of treatment and censoring.
Stabilization with baseline indicators yielded an appropriate
weight distribution (mean, 1.04; standard deviation; 0.24; range,
0.27–13.02) [25].The final structural model was estimated using
pooled logistic regression to approximate a discrete time haz-
ards model [26] using robust standard errors and independent
correlation matrices. Note that our marginal structural model
included adjustment for baseline covariates in the final model
as well as in the weights (which is typical [25–27]); as such,
comparisons between the baseline-adjusted-and-weighted mar-
ginal structural model and the baseline-adjusted-but-unweighted
model allowed us to assess the extent of confounding attributable
to time-varying confounders alone.
Hazard ratios (HRs) from the marginal structural model were
compared with those of a crude unweighted model and an ad-
justed unweighted model for residual confounding by baseline
variables identified by directed acyclic graphs [28]. Additional
analyses stratified estimates using interacting terms for index
partner characteristics including time period (2006–2008 vs
2009 onward, to reflect periods before and after availability of
second line ART), biological sex, baseline CD4, and type of
treatment clinic. The assumption of proportional hazards was
relaxed after inspection of the log-log survival curve by interact-
ing our time and exposure variables.
Ethical Approval
All data used for this analysis were collected as part of prefec-
tural disease control efforts. Ethical approval for the analysis of
this data for research purposes was provided by the Institutional
Review Board of the National Center for AIDS/STD Control




The final analysis included 4916 couples with a mean follow-up
of 5.4 years (Table 1). The median age of index partners was
44 years (interquartile range: 40–49), and 45.7% were men.
About half of index patients (46.8%) were thought to have been in-
fected through blood or plasma donation. Over 90% of subjects re-
ported “farmer” as the primary occupation. Most subjects (68.9%)
had 6 or fewer years of education. Of the 94.8% (N = 4662) couples
who reported any sex in the past year at most recent visit, 63.3% of
them (N = 3115) reported “always” using condoms. All HIV-
infected index partners were treatment naive at baseline (by
study design), but by 2012 over 80% were receiving ART.
Few nonindex partners reported any risks associated with
HIV acquisition risk outside the partnership. Over 7 years of
follow-up, only 32 (0.7%) reported any episode of extramarital
sex, in which condom use was reported as perfect in all but 1
case. Information on past diagnoses of sexually transmitted in-
fections was collected for the first time in 2012, which showed
that only 13 nonindex partners (0.4%) had received such a di-
agnosis in the previous year. No nonindex partners reported
any type of illicit drug use throughout the study.
Main Analyses
In 26 389 years of follow-up, we observed 157 seroconversions
(overall incidence rate, 0.59 cases per 100 person-years [PY];
95% confidence interval [CI], .51–.70; Table 2). Of these sero-
conversions, 84 occurred after the index partner had initiated
ART (incidence rate, 0.43 per 100 PY; 95% CI, .35–.53) and
73 before (incidence rate, 5.87 per 100 PY; 95% CI, 4.65–7.42;
Table 2). Couples who seroconverted were more likely to be
farmers, report more frequent sex (3 or more episodes a month
over the last year vs fewer) and report “sometimes” or “never”
having used condoms (vs “always”) in the past year. Couples
whose index partners were diagnosed with HIV longer than
5 years before their most recent visit, and whose partner se-
roconverted before 2009 experienced higher rates of HIV
transmission.
In unadjusted Cox models, ART reduced the risk of HIV in
treated couples by 29% (HR, 0.71; 95% CI, .52–.97); however,
weighting couples by their inverse probability of treatment
and censoring weights increased this protective effect to and
48% (HR, 0.52; 95% CI, .34–.82). Most of the change in estimate
was due to adjustment for baseline factors rather than from con-
trol of time-varying confounding through weighting, as suggest-
ed by similarity of results between weighted (HR, 0.52) and
unweighted (HR, 0.51; 95% CI, .34–.79) models, both of
which adjusted for baseline covariates (Figure 1).
Stratified Analyses
In our stratified analyses, in which models were weighted and
adjusted for baseline covariates, we observed the most substan-
tial difference in effect of ART over time. Specifically, we saw a
modest benefit from ART on transmission in the early period
from 2006 to 2008 (HR, 0.68; 95% CI, .34–1.36), and a far
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stronger effect in the later period from 2009 to 2012 (HR, 0.33,
95% CI, .20–.55). This evolving effect is also captured in the di-
vergent survival curves of Figure 2, which are adjusted with the
same inverse probability of treatment and censoring weights as
in the marginal structural model [27]. ART also appeared to
lower transmission risk more for index partners initiating
ART at CD4 cell count at 250 or higher (HR, 0.41; 95% CI,
.22–.79) rather than below 250 (HR, 0.98; 95% CI, .54–1.78).
We saw no substantive differences across index partner sex or
type of treatment center. Stratified results are summarized in
Figure 1.
DISCUSSION
We observed that ART reduced the overall HIV transmission
risk in serodiscordant couples in rural China by 48%. Crucially,
this effect evolved over time, with minimal protection from
ART in the earlier phase of the study (2006–2008), and a strong
preventive effect taking hold from 2009 to 2012. Notably, our
time-specific results were consistent with findings from the 2
previous analyses of the same cohort, the first which found a
modest effect in the early phase (2006–2008) [15], and the sec-
ond which reported a strong effect in the later phase (2007–
2011) [16]. We posit 2 plausible explanations for the dramatic
change in effect over time: (1) reduced use of less tolerable an-
tivirals such as didanosine, which were common in the early
years of the ART program [29] (but which could not be directly
assessed in this study given the low prevalence of use in later
years of observation); and (2) systems-level improvements
over time, such as enhancements in the ART delivery system
[30] or increased medication adherence support [31].
The dramatic improvement in the protectiveness of ART over
time also highlights a key pitfall of causal conclusions drawn
from single summary HR estimates, which are often poor
Table 1. Characteristics of the 4916 HIV Serodiscordant Couples Included in the Final Analysis
Seroconversion No Seroconversion Total
N = 157 (%) N = 4759 (%) N = 4916 (%)
Male index partner 69 (43.9) 2177 (45.7) 2246 (45.7)
Missing 2 (1.3) 95 (2.0) 97 (2.0)
Index partner age over 45 84 (53.5) 2255 (47.4) 2339 (47.6)
Index partner HIV transmission route
Blood/plasma donation 101 (64.3) 2301 (48.4) 2402 (46.8)
Blood transfusion 10 (6.4) 705 (14.8) 715 (14.5)
Injection drug use 4 (2.5) 122 (2.6) 126 (2.6)
Hetero or homosexual sex 18 (11.5) 1270 (26.7) 1288 (26.2)
Missing 24 (15.3) 461 (9.7) 485 (9.9)
Index partner occupation as “farmer” 153 (97.5) 4307 (90.5) 4460 (90.7)
Missing 2 (1.3) 100 (2.1) 102 (2.1)
Index partner education level
Primary or less 86 (54.8) 3299 (69.3) 3385 (68.9)
More than primary 58 (36.9) 948 (19.9) 1006 (20.5)
Missing 13 (8.3) 512 (10.8) 525 (10.7)
Average monthly frequency of intra-couple sex in the past year
0–2 times 11 (.7.0) 1429 (30.0) 1440 (29.3)
3 or more times 140 (89.2) 3209 (67.4) 3349 (45.7)
Missing 6 (3.8) 272 (5.7) 278 (5.7)
Condom use in last year
“Always” 36 (22.9) 2871 (60.3) 2907 (59.1)
“Sometimes” or “never” 18 (11.5) 179 (3.8) 197 (4.0)
Missing 103 (65.6) 1709 (35.9) 1812 (36.9)
Index partner baseline CD4 <250 cells/mL 66 (42.0) 1520 (31.9) 1586 (32.3)
Missing 25 (15.9) 504 (10.6) 529 (10.8)
Time since index HIV diagnosis under 5 years
<5 yr since last follow-up 5 (3.2) 496 (10.4) 501 (10.2)
Missing 19 (12.1) 105 (2.2) 124 (2.5)
Index partner ART use (ever) 101 (64.3) 3851 (80.9) 3952 (80.4)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus.
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representations of period-specific effects, particularly if ratios
shift over time [32]. Our plot of weighted survival curves (Fig-
ure 2) showing divergent, nonparallel curves, confirms that
this in fact the case of our study, which not only undermines
the proportional hazards assumption necessary for valid use
of Cox models but also calls into question the value of interpret-
ing effects that span time periods during which treatment envir-
onments underwent substantial changes. Nevertheless, the
apparent improvement in ART effectiveness in Henan in spite
of its resource limitations is encouraging, and whether this
might be due to factors such as cumulative clinician experience
or innovations in low cost service delivery is a possible area for
further research. In other settings where treatment conditions
may have improved as rapidly as in rural China, we urge consi-
deration of weighted survival curves [27] over single HRs to
disseminate observational findings on treatment for HIV
prevention.
The lack of a protective effect of ART in couples whose index
partner initiated therapy with a CD4 cell count below 250 is also
noteworthy, though further research will need to explore possi-
ble explanations, such as compromised suppressive potential of
ART in sicker patients, or systematically poorer drug adherence
in this group. In the meantime these results support program-
ming decisions to provide specialized monitoring for such cou-
ples to receive additional drug adherence support and safe sex
counseling.
Our report expands on 2 previous analyses of the same pop-
ulation from Henan [15, 16], with several key differences. By
using all available years of data (2006–2012) and by including
65% more eligible couples than either study, our study mitigated
selection bias. We also minimized misclassification by validating
exposure and outcome data using national disease control data-
bases and by considering ART use as a time varying exposure (vs
status at last visit). We also restricted our analysis to couples still
unexposed to ART at enrollment with a new user design in order
to establish clear temporality between baseline confounding var-
iables, ART use, and transmission. Finally, weighting of models
with visit-specific inverse probabilities of treatment and censor-
ing mitigated bias due to time-varying confounding.
Our estimate of the effect of ART on HIV transmission risk
was far less optimal than that reported by a meta-analysis of cou-
ples taking ART in other low-income countries (48% vs 86%)
[33], and even our most optimal estimate of a 67% reduction
in the later years of observation is still more modest than effects
observed elsewhere. The difference is most likely because the lat-
ter studies reflected experiences of couples managed under spe-
cial conditions as part of scientific research studies [34–36]. By
contrast, couples in our study were treated through China’s gov-
ernment administered ART program, in which many received
care from nonphysicians in basic rural healthcare clinics. Differ-
ences across these 2 types of settings may matter for successful
use of treatment as prevention, and underscore the need for
more investigations in settings like Henan and Uganda [14] to
inform real world implementation challenges.







Sex of index partner
Male 69 12 045 0.57 (.45–.72)
Female 86 13 915 0.62 (.50–.76)
Missing 2 429 0.47 (.12–1.86)
Age of index partner
<45 73 14 072 0.52 (.41–.65)
≥45 84 12 317 0.68 (.55–.84)
Index partner HIV transmission route
Blood/plasma donation 101 12 115 0.83 (.69–1.01)
Blood transfusion 10 4084 0.24 (.13–.45)
Injection drug use 4 710 0.56 (.21–1.50)
Hetero or homosexual sex 18 7294 0.25 (.16–.39)
Missing 24 2186 1.10 (.73–1.63)
Index partner occupation
Farmer 153 24 015 0.64 (.54–.75)
Nonfarmer 2 1923 0.10 (.02–.42)
Missing 2 451 0.44 (.11–1.77)
Index partner education level
Primary or less 73 18 454 0.40 (.31–.50)
More than primary 13 2699 0.48 (.28–.83)
Missing 71 5236 1.36 (1.08–1.71)
Average monthly frequency of intra-couple sex in the past year
0–2 times 124 15 456 0.80 (.67–.96)
3 or more times 29 9370 0.31 (.22–.45)
Missing 4 1563 0.26 (.10–.68)
Condom use in last year
“Always” 54 15 981 0.34 (.26–.44)
“Sometimes or never” 25 840 2.98 (2.02–4.38)
Missing 78 9568 8.15 (.65–1.02)
Index partner baseline CD4
<250 66 8651 0.76 (.60–.97)
≥250 66 15 747 0.42 (.33–.53)
Missing 25 1991 1.26 (.85–1.85)
Estimated time of index HIV diagnosis
<5 yr 5 1923 0.26 (.10–.62)
≥5 yr 133 22 978 0.58 (.49–.69)
Missing 19 488 3.89 (2.51–6.05)
Index ART user (ever)
Yes 90 20 769 0.43 (.35–.53)
No 66 1124 5.87 (4.65–7.42)
Time period
2008 and earlier 86 10 160 0.85 (.69–1.04)
After 2008 71 16 229 0.44 (.35–.55)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human
immunodeficiency virus; PY, person-year.
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The consistency of our results with couples elsewhere in
China are noteworthy (Table 3), less for the fact that they are
all from the same country than for the fact that all were recip-
ients of government healthcare. In a nationally representative
sample of over 38 000 couples, for example, ART was shown
to have reduced transmission by 26% between 2003 and 2011
[37]. In a second report from Yunnan province, investigators re-
ported a 66% reduction of virologically linked transmissions
between 2009 and 2011 attributable to ART in index partners
[13]. Results from each of these reports roughly correspond to
our results from the earlier and later phases of follow-up (32%
and 67% reduction, respectively).
HIV treatment as administered in resource limited settings
like rural China appears to be an important means of HIV pre-
vention in the real world. The public health applicability of
these results will need to consider the uniqueness of this
Figure 1. Hazard ratios (HRs) and 95% confidence intervals (CIs) for crude, sensitivity analysis, and stratified analyses. All stratified analyses (including by
time period) are weighted by inverse probabilities of treatment and censoring. All models use multiply imputed data for variables missing more than 20%.
Adjustment for the baseline characteristics of the index partner including age, sex, education, disease stage, and time period.
Figure 2. Inverse probability of treatment and censoring weighted Kaplan–Meir survival curves comparing treated and untreated experiences of couples. The
same curves are shown on 2 different scales (0 to 1 on the left and 0.9 to 1.0 on the right) to better display trends. Abbreviation: ART, antiretroviral therapy.
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Table 3. Comparison of Longitudinal Studies Assessing the Effect the ART on HIV Transmission in Serodiscordant Couples in China
Author [Year]
Number of
Couples Region Time Period
Exposure Assessment
in Index Partnera
Methods for Control of Confounding
Bias
Estimate of Effect of ART in
Index Partner on Risk of HIV
Transmission HR (95% CI) Conclusion




2006–2008 Ever vs never exposed
to ART.
Longitudinal follow-up of couples in a
region where most indexes were
infected through blood donation.
Unadjusted HR = 0.76
(.45–1.28).
ART did not effectively
prevent HIV transmission
over two years of follow-
up.




2007–2011 1) Ever vs never
exposed to ART;
Longitudinal follow-up of couples in a
region where most indexes were
infected through blood donation.
1) Ever v never: adjusted
HR= 0.01 (.00–.12);
ART was protective against




at most recent visit.
2) ART at last visit: adjusted
HR= 0.05 (.01–.16).b




2009–2011 ART initiated before
midpoint of study,




with outcome (P< .10); forced
entry of frequency of sex in 12 mo
and HSV-2 status .
Unadjusted HR = 0.34
(.12–.97);
ART was protective against
HIV transmission over two
years of follow-up.Adjusted HR = 0.30 (.10–.86).c
Jia Z et al
(2013) [34]
38 862 National 2003–2011 ART exposed at




from national epidemiology and
treatment databases.
Unadjusted HR = 0.61
(.55–.67);





Adjusted HR = 0.74 (.65–.84).d
Current analysis 4916 Henan
Province
2006–2012 ART exposure as a
time-varying
variable.
Inverse probability of treatment and
censoring weighting to address
time-varying confounders
identified through use of directed
acyclic graphs.
Overall HR is not proportional ART efficacy for HIV
prevention varied over
time.
Weight-adjusted HR for 2006
to 2008 effect, HR = 0.86
(.69–1.04); for 2009 to 2012
effect, HR = 0.44 (.35–.55).
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; HSV, herpes simplex virus.
a Outcome for all models is HIV seroconversion estimated as midpoint between last negative and first positive HIV antibody test.
b Adjusted for duration of follow-up, sex, age, education, marital status, occupation, route of HIV infection, and baseline CD4 cell count of the index patient.
c Adjusted for education, sexual frequency, condom use, last recorded CD4 cell count, AIDS, last recorded viral load, and ever taken ART.














population and our limited ability to verify some measures. The
HIV population of Henan is largely made up of older persons
with low reported rates of drug use or sexual promiscuity [30]
(corroborated by low rates of syphilis or reported sexually
transmitted infection-like symptoms in our cohort), limiting
generalizability to groups with more frequent or multiple
sources of HIV exposure, such as sex workers who use drugs.
These same features, however, also make seroconversions ob-
served in our study population likely true representations of
HIV transmission between primary partners, a hypothesis
that could ideally have been confirmed through phylogenetic
linkage analysis had useable samples of stored plasma been
available. Other data limitations precluded investigation of hy-
potheses about differential ART effectiveness across subgroups.
Future investigations will therefore benefit from collection of
more details on index partner treatment experiences (ie, drug
regimens, viral load, or medication adherence) or evolution of
the local healthcare environment (ie, healthcare budget expen-
ditures or staffing) to explore mechanisms driving potential ef-
fect modification.
In summary, we find that ART treatment of infected pa-
tients reduced HIV transmission. The magnitude and durabil-
ity of benefit will depend on availability of well tolerated
antiretroviral agents, a sufficient healthcare infrastructure,
and constant adherence to medication. The experience in
China suggests that these requirements can be met even in
poor and remote locations.
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